Anebulo appoints part-time CFO Daniel George replacing Sandra Gardiner effective Sept 28

Anebulo Pharmaceuticals, Inc.

Daniel George appointed part-time CFO, principal financial and accounting officer; replaces Sandra A. Gardiner.
Compensation at $400/hour; typical schedule up to 10 hours per week, remote from Morgan Hill, CA.
Mr. George previously CFO of Lucira Health (2020-2022) and runs a consulting practice since Dec 2022.
Offer letter filed as Exhibit 10.1 includes standard at-will and arbitration provisions.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Sandra A. Gardiner

Chief Financial Officer

ANEB · Anebulo Pharmaceuticals, Inc.

Effective: 2023-09-28
Successor: Daniel George
Filed: September 29, 2023, 7:59 PM ET

On September 26, 2023, Anebulo Pharmaceuticals, Inc., a Delaware corporation (the “Company”), appointed Daniel George as the Company’s part-time Chief Financial Officer, as well as the Company’s principal financial officer and principal accounting officer, effective September 28, 2023, replacing Sandra A. Gardiner in such capacities.

Appointed

Daniel George

part-time Chief Financial Officer

ANEB · Anebulo Pharmaceuticals, Inc.

Effective: 2023-09-28
Filed: September 29, 2023, 7:59 PM ET

On September 26, 2023, Anebulo Pharmaceuticals, Inc., a Delaware corporation (the “Company”), appointed Daniel George as the Company’s part-time Chief Financial Officer, as well as the Company’s principal financial officer and principal accounting officer, effective September 28, 2023, replacing Sandra A. Gardiner in such capacities.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Sandra A. Gardiner departed as Chief Financial Officer at Anebulo Pharmaceuticals, Inc..

Action: replaced
Role: Chief Financial Officer

Exact text from the filing

On September 26, 2023, Anebulo Pharmaceuticals, Inc., a Delaware corporation (the “Company”), appointed Daniel George as the Company’s part-time Chief Financial Officer, as well as the Company’s principal financial officer and principal accounting officer, effective September 28, 2023, replacing Sandra A. Gardiner in such capacities.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Daniel George was appointed as part-time Chief Financial Officer at Anebulo Pharmaceuticals, Inc..

Action: appointed
Role: part-time Chief Financial Officer

Exact text from the filing

On September 26, 2023, Anebulo Pharmaceuticals, Inc., a Delaware corporation (the “Company”), appointed Daniel George as the Company’s part-time Chief Financial Officer, as well as the Company’s principal financial officer and principal accounting officer, effective September 28, 2023, replacing Sandra A. Gardiner in such capacities.

View on SEC.gov

Anebulo Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-034696

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.